2-Chloro-6-fluoro-N-hydroxybenzimidoyl Chloride - CAS 51088-25-6
Catalog: |
BB062438 |
Product Name: |
2-Chloro-6-fluoro-N-hydroxybenzimidoyl Chloride |
CAS: |
51088-25-6 |
Synonyms: |
N-[(Chloro)(2-chloro-6-fluorophenyl)methylene]hydroxyamine; α,2-Dichloro-6-fluorobenzaldoxime; 2-Chloro-6-fluoro-N-hydroxybenzenecarboximidoyl Chloride |
IUPAC Name: | (1Z)-2-chloro-6-fluoro-N-hydroxybenzenecarboximidoyl chloride |
Description: | 2-Chloro-6-fluoro-N-hydroxybenzimidoyl Chloride is an intermediate in the synthesis of inhibitors for treating autoimmune inflammations. |
Molecular Weight: | 208.02 |
Molecular Formula: | C7H4Cl2FNO |
Canonical SMILES: | C1=CC(=C(C(=C1)Cl)C(=NO)Cl)F |
InChI: | InChI=1S/C7H4Cl2FNO/c8-4-2-1-3-5(10)6(4)7(9)11-12/h1-3,12H/b11-7- |
InChI Key: | XQUJVGVNTYDLIG-XFFZJAGNSA-N |
Solubility: | Chloroform, Methanol |
Appearance: | White Solid |
References: | PCT Int. Appl. (2012), WO 2012101261 A1 20120802.. |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P260, P261, P264, P264+P265, P270, P272, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P330, P333+P313, P362+P364, P363, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
AU-2018330633-A1 | 1-(4-(isoxazol-5-YL)-1H-pyrazol-1-YL)-2-methylpropan-2-OL derivatives and related compounds as IL-17 and IFN-gamma inhibitors for treating autoimmune diseases and chronic inflammation | 20170906 |
IL-273064-D0 | Derivatives 1- (4- (isoxazol-5-il) - h1-pyrazol-1-il) -2-methylpropan-2-ol and related compounds as IL-17 and ifn-gamma suppressors for the treatment of autoimmune diseases and chronic inflammation | 20170906 |
WO-2019048541-A1 | 1- (4- (ISOXAZOL-5-YL) -1H-PYRAZOL-1-YL) -2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF IL-17 AND IFN- GAMMA FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 20170906 |
EP-3679034-A1 | 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation | 20170906 |
KR-20200069299-A | 1-(4-(isoxazol-5-yl)-1H-pyrazol-1-yl)-2-methylpropan-2- as an IL-17 and IFN-gamma inhibitor to treat autoimmune diseases and chronic inflammation All derivatives and related compounds | 20170906 |
AU-2018330633-B2 | 1-(4-(isoxazol-5-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-OL derivatives and related compounds as IL-17 and IFN-gamma inhibitors for treating autoimmune diseases and chronic inflammation | 20170906 |
US-2021061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | 20170906 |
AU-2018330633-C1 | 1-(4-(isoxazol-5-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-OL derivatives and related compounds as IL-17 and IFN-gamma inhibitors for treating autoimmune diseases and chronic inflammation | 20170906 |
US-2019233420-A1 | Hormone receptor modulators for treating metabolic conditions and disorders | 20160823 |
US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | 20160823 |
Complexity: | 188 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 1 |
Exact Mass: | 206.9653973 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 206.9653973 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 32.6Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 3.3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS